ArticleCureus2024
Intraocular Inflammation Following Intravitreal Faricimab Injection in Neovascular Age-Related Macular Degeneration.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative outcomes of intracorporeal and extracorporeal urinary diversion in robotic cystectomy: a systematic review and meta-analysis.Journal of robotic surgery · 2025Pooled it
- Clinical characteristics and outcomes of intraocular inflammation following intravitreal faricimab for neovascular age-related macular degeneration: a single-centre retrospective study.Eye (London, England) · 2026Article
- Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy.International ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We herein report intraocular inflammation (IOI) following intravitreal (IVT) faricimab injection in three patients. A 73-year-old male, a 68-year-old female, and an 82-year-old female, all diagnosed with neovascular age-related macular degeneration (AMD), had received multiple anti-vascular endothelial growth factor (anti-VEGF) injections for the same. They were injected with IVT faricimab due to non-response to other agents. Following IVT faricimab, two patients presented with mild vitritis (grade 2) within three days post-injection, and one patient presented with anterior uveitis on day 1. No associated retinal vasculitis or occlusion was present. All patients responded well to topical steroid therapy. Notably, the 68-year-old lady had a history of IOI (mild vitritis) following a single IVT brolucizumab in the past. The other two patients had not received IVT brolucizumab earlier. IOI after IVT faricimab has been reported a few times previously. One must be aware of the spectrum of presentation (vitritis, anterior uveitis, panuveitis, vascular occlusion, vasculitis) and be vigilant to provide timely management, especially in sight-threatening cases. A history of IOI following previous brolucizumab injection needs to be evaluated further for possible immunological mechanisms at play.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.